KR100885129B1 - 위장관의 기질 종양의 치료 - Google Patents

위장관의 기질 종양의 치료 Download PDF

Info

Publication number
KR100885129B1
KR100885129B1 KR1020037003903A KR20037003903A KR100885129B1 KR 100885129 B1 KR100885129 B1 KR 100885129B1 KR 1020037003903 A KR1020037003903 A KR 1020037003903A KR 20037003903 A KR20037003903 A KR 20037003903A KR 100885129 B1 KR100885129 B1 KR 100885129B1
Authority
KR
South Korea
Prior art keywords
treatment
salt
patients
acid
gist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020037003903A
Other languages
English (en)
Korean (ko)
Other versions
KR20030051656A (ko
Inventor
엘리자베스 부흐던게르
레나우드 카프데빌레
조지 다니엘 데메트리
사사 디미트리제빅
브라이언 제이 드루커
조나단 에이. 플레쳐
헤익키 조엔수
산드라 레타 실버만
데이비드 투베손
마이클 씨. 하인리히
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22920224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100885129(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20030051656A publication Critical patent/KR20030051656A/ko
Application granted granted Critical
Publication of KR100885129B1 publication Critical patent/KR100885129B1/ko
Assigned to 다나-파버 캔서 인스티튜트 인크., 오레곤 헬스 사이언시즈 유니버시티, 브리검앤드위민즈하스피탈, 인코포레이티드 reassignment 다나-파버 캔서 인스티튜트 인크. 권리의 일부이전등록 Assignors: 노파르티스 아게
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Farming Of Fish And Shellfish (AREA)
KR1020037003903A 2000-10-27 2001-10-26 위장관의 기질 종양의 치료 Ceased KR100885129B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24381000P 2000-10-27 2000-10-27
US60/243,810 2000-10-27
PCT/EP2001/012442 WO2002034727A2 (en) 2000-10-27 2001-10-26 Treatment of gastrointestinal stromal tumors

Publications (2)

Publication Number Publication Date
KR20030051656A KR20030051656A (ko) 2003-06-25
KR100885129B1 true KR100885129B1 (ko) 2009-02-23

Family

ID=22920224

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037003903A Ceased KR100885129B1 (ko) 2000-10-27 2001-10-26 위장관의 기질 종양의 치료

Country Status (25)

Country Link
US (1) US6958335B2 (https=)
EP (1) EP1332137B1 (https=)
JP (1) JP4386635B2 (https=)
KR (1) KR100885129B1 (https=)
CN (1) CN1276754C (https=)
AT (1) ATE321556T1 (https=)
AU (2) AU1826202A (https=)
BR (1) BRPI0114870B8 (https=)
CA (1) CA2424470C (https=)
CY (1) CY1105055T1 (https=)
CZ (1) CZ303944B6 (https=)
DE (1) DE60118430T2 (https=)
DK (1) DK1332137T3 (https=)
ES (1) ES2260317T3 (https=)
HU (1) HU229106B1 (https=)
IL (2) IL155029A0 (https=)
MX (1) MXPA03003703A (https=)
NO (1) NO324948B1 (https=)
NZ (1) NZ525254A (https=)
PL (1) PL209733B1 (https=)
PT (1) PT1332137E (https=)
RU (1) RU2301066C2 (https=)
SK (1) SK287335B6 (https=)
WO (1) WO2002034727A2 (https=)
ZA (1) ZA200302155B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220015672A (ko) 2020-07-31 2022-02-08 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
PT1392313E (pt) * 2001-05-16 2007-07-17 Novartis Ag Combinação que compreende n - ( 5- [ 4- ( metil-piperazinomrtil ) - benxoilamido ] - 2 -metilfenil ) - 4 -( 3 - piridil ) - 2 - pirimidina-amina e um agente quimioterapêutico
DE60215648T2 (de) * 2001-06-29 2007-08-23 Ab Science Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
EP1401412A2 (en) * 2001-06-29 2004-03-31 AB Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
ES2266553T3 (es) * 2001-06-29 2007-03-01 Ab Science Utilizacion de derivados de la n-fenil-2-pirimidina-amina para tratar las enfermedades inflamatorias.
JP2004537536A (ja) * 2001-06-29 2004-12-16 アブ サイエンス アレルギー疾患を治療するためのチロシンキナーゼ阻害剤の使用方法
JP2005500041A (ja) * 2001-06-29 2005-01-06 アブ サイエンス 強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤
DE60227701D1 (de) * 2001-09-20 2008-08-28 Ab Science Die verwendung von c-kithemmern zur förderung des haarwuchses
EP1427379B1 (en) * 2001-09-20 2008-08-13 AB Science Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
DK1478380T3 (da) * 2002-02-27 2006-11-27 Ab Science Anvendelse af tyrosinkinase-inhibitorer til behandling af CNS-lidelser
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
CA2538523A1 (en) * 2003-09-19 2005-03-31 Novartis Ag Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
US20100210596A1 (en) * 2006-02-01 2010-08-19 Bluestone Jeffrey A Use of aminopyrimidine compounds in the treatment of immune disorders
EP2061772A4 (en) * 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
AU2007296743B2 (en) * 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US20090082361A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched imatinib
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
US8530492B2 (en) 2009-04-17 2013-09-10 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
BR112013022552B1 (pt) 2011-03-04 2021-11-23 Newgen Therapeutics, Inc Compostos de quinazolina substituídos com alcino, seu uso, composição farmacêutica, e kit
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
US20160015708A1 (en) 2012-02-21 2016-01-21 Ranbaxy Laboratories Limited Stable dosage forms of imatinib mesylate
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
BR112015001838B1 (pt) 2012-07-27 2022-10-25 Izumi Technology, Llc Composição de inibidor de efluxo
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
US11285152B2 (en) 2017-07-20 2022-03-29 Kashiv Biosciences, Llc Stable oral pharmaceutical composition of imatinib
IL276398B2 (en) 2018-01-31 2026-03-01 Deciphera Pharmaceuticals Llc Combination therapy for mastocytosis
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
EP3938363A1 (en) 2019-03-11 2022-01-19 Teva Pharmaceuticals International GmbH Solid state forms of ripretinib
EP4725489A2 (en) 2019-08-02 2026-04-15 OneHealthCompany, Inc. Treatment of canine cancers
PT4013412T (pt) 2019-08-12 2026-03-18 Deciphera Pharmaceuticals Llc Ripretinib para o tratamento de tumores estromais gastrointestinais
LT4013412T (lt) 2019-08-12 2026-03-25 Deciphera Pharmaceuticals, Llc Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui
HRP20231699T1 (hr) 2019-12-30 2024-05-10 Deciphera Pharmaceuticals, Llc Formulacije inhibitora amorfne kinaze i postupci njihove primjene
CN115243681B (zh) 2019-12-30 2024-08-16 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003854A1 (en) * 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1528449A1 (ru) * 1985-06-05 1989-12-15 Центральный институт усовершенствования врачей Способ релаксации илеоцекального отдела кишечника
TW225528B (https=) * 1992-04-03 1994-06-21 Ciba Geigy Ag
JP2002523455A (ja) * 1998-08-31 2002-07-30 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節剤としての幾何学的に制限された２−インドリノン誘導体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003854A1 (en) * 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220015672A (ko) 2020-07-31 2022-02-08 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
US12582639B2 (en) 2020-07-31 2026-03-24 Pharos Ibio Co., Ltd. Preventive, relief or therapeutic use of 2,3,5-substituted thiophene compound against gastrointestinal stromal tumor

Also Published As

Publication number Publication date
US20040023976A1 (en) 2004-02-05
CY1105055T1 (el) 2010-03-03
NO20031833D0 (no) 2003-04-24
WO2002034727A3 (en) 2003-03-27
BRPI0114870B8 (pt) 2021-05-25
AU2002218262B2 (en) 2005-09-29
ES2260317T3 (es) 2006-11-01
PT1332137E (pt) 2006-07-31
US6958335B2 (en) 2005-10-25
JP4386635B2 (ja) 2009-12-16
CA2424470A1 (en) 2002-05-02
JP2004512328A (ja) 2004-04-22
KR20030051656A (ko) 2003-06-25
IL155029A0 (en) 2003-10-31
CN1622808A (zh) 2005-06-01
EP1332137B1 (en) 2006-03-29
DE60118430D1 (de) 2006-05-18
NO324948B1 (no) 2008-01-07
IL155029A (en) 2009-09-22
AU1826202A (en) 2002-05-06
DK1332137T3 (da) 2006-07-17
CN1276754C (zh) 2006-09-27
ZA200302155B (en) 2004-04-22
ATE321556T1 (de) 2006-04-15
CZ20031152A3 (en) 2004-04-14
WO2002034727A2 (en) 2002-05-02
HK1058193A1 (en) 2004-05-07
SK287335B6 (sk) 2010-07-07
CZ303944B6 (cs) 2013-07-10
CA2424470C (en) 2009-06-09
BR0114870A (pt) 2004-02-17
EP1332137A2 (en) 2003-08-06
PL209733B1 (pl) 2011-10-31
SK5182003A3 (en) 2004-02-03
MXPA03003703A (es) 2005-01-25
RU2301066C2 (ru) 2007-06-20
BRPI0114870B1 (pt) 2020-06-16
DE60118430T2 (de) 2006-10-26
NZ525254A (en) 2006-02-24
NO20031833L (no) 2003-04-24
HU229106B1 (en) 2013-07-29
PL362148A1 (en) 2004-10-18
HUP0301512A2 (hu) 2003-11-28

Similar Documents

Publication Publication Date Title
KR100885129B1 (ko) 위장관의 기질 종양의 치료
AU2002218262A1 (en) Treatment of gastrointestinal stromal tumors
RU2672585C2 (ru) Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака
Anders et al. Cyclophosphamide in treatment of disseminated malignant disease
BOURONCLE et al. Evaluation of CB 1348 in Hodgkin's disease and allied disorders
JP7278405B2 (ja) 小細胞肺がんの治療におけるキアウラニブの使用
WO2019242688A1 (zh) 3-羟基氨基苯甲酸与索拉非尼联合用药治疗肿瘤
SPIES et al. Vitamin B6 (Pyridoxin) Deficiency in Human Beings: Further Studies, with Special Emphasis on the Urinary Excretion of Pyridoxin
South-East European Oncology Group (SEEOG) et al. Phase II study of 4′-epi-doxorubicin in patients with untreated, extensive small cell lung cancer
HK1058193B (en) Treatment of gastrointestinal stromal tumors
CN117396202A (zh) 给药方案
Mittal et al. Acute transient cerebral toxicity associated with administration of high-dose methotrexate
CN121401261A (zh) 喹诺林化合物治疗甲状腺癌的用途
CN108472293A (zh) 用于癌症的联合疗法
KR20240141067A (ko) 표적 단백질 및 표적 분해 단백질에 결합하는 화합물, 이를 유효성분으로 함유하는 약학적 조성물, 및 이의 용도
Olweny Goals and rationale of cancer treatment
HK40110657A (zh) 用於治疗癌症的cdk4抑制剂
Beleslin et al. Action of drugs on the human colonic preparations of Hirschsprung's disease

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20030318

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20061025

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20070928

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20080623

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20081114

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20090217

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20090218

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20120203

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20120203

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20130117

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20130117

Start annual number: 5

End annual number: 5

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

Patent event date: 20130201

Comment text: Request for Trial

Patent event code: PJ02042R01D

Patent event date: 20090217

Comment text: Registration of Establishment

Patent event code: PJ02041E01I

Appeal kind category: Invalidation

Request date: 20130201

Decision date: 20140610

Appeal identifier: 2013100000257

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

Patent event date: 20130322

Comment text: Request for Trial

Patent event code: PJ02042R01D

Patent event date: 20090217

Comment text: Registration of Establishment

Patent event code: PJ02041E01I

Appeal kind category: Invalidation

Request date: 20130322

Decision date: 20140610

Appeal identifier: 2013100000688

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

Patent event date: 20130325

Comment text: Request for Trial

Patent event code: PJ02042R01D

Patent event date: 20090217

Comment text: Registration of Establishment

Patent event code: PJ02041E01I

Appeal kind category: Invalidation

Request date: 20130325

Decision date: 20140610

Appeal identifier: 2013100000708

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

Patent event date: 20130516

Comment text: Request for Trial

Patent event code: PJ02042R01D

Patent event date: 20090217

Comment text: Registration of Establishment

Patent event code: PJ02041E01I

Appeal kind category: Invalidation

Request date: 20130516

Decision date: 20140610

Appeal identifier: 2013100001309

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

Appeal kind category: Invalidation

Request date: 20130603

Decision date: 20140610

Appeal identifier: 2013100001468

Patent event date: 20130603

Comment text: Request for Trial

Patent event code: PJ02042R01D

Patent event date: 20090217

Comment text: Registration of Establishment

Patent event code: PJ02041E01I

Appeal kind category: Invalidation

Request date: 20130603

Decision date: 20140610

Appeal identifier: 2013100001467

J204 Request for invalidation trial [patent]
PJ0204 Invalidation trial for patent

Patent event date: 20130711

Comment text: Request for Trial

Patent event code: PJ02042R01D

Patent event date: 20090217

Comment text: Registration of Establishment

Patent event code: PJ02041E01I

Appeal kind category: Invalidation

Request date: 20130711

Decision date: 20140610

Appeal identifier: 2013100001855

FPAY Annual fee payment

Payment date: 20140121

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20140121

Start annual number: 6

End annual number: 6

J301 Trial decision

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20130603

Effective date: 20140610

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20130201

Effective date: 20140610

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20130325

Effective date: 20140610

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20130516

Effective date: 20140610

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20130322

Effective date: 20140610

Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20130711

Effective date: 20140610

Free format text: TRIAL NUMBER: 2013100000257; TRIAL DECISION FOR INVALIDATION REQUESTED 20130201

Effective date: 20140610

Free format text: TRIAL NUMBER: 2013100000688; TRIAL DECISION FOR INVALIDATION REQUESTED 20130322

Effective date: 20140610

Free format text: TRIAL NUMBER: 2013100000708; TRIAL DECISION FOR INVALIDATION REQUESTED 20130325

Effective date: 20140610

Free format text: TRIAL NUMBER: 2013100001309; TRIAL DECISION FOR INVALIDATION REQUESTED 20130516

Effective date: 20140610

Free format text: TRIAL NUMBER: 2013100001467; TRIAL DECISION FOR INVALIDATION REQUESTED 20130603

Effective date: 20140610

Free format text: TRIAL NUMBER: 2013100001468; TRIAL DECISION FOR INVALIDATION REQUESTED 20130603

Effective date: 20140610

Free format text: TRIAL NUMBER: 2013100001855; TRIAL DECISION FOR INVALIDATION REQUESTED 20130711

Effective date: 20140610

PJ1301 Trial decision

Appeal kind category: Invalidation

Request date: 20130711

Decision date: 20140610

Appeal identifier: 2013100001855

Appeal kind category: Invalidation

Request date: 20130603

Decision date: 20140610

Appeal identifier: 2013100001468

Appeal kind category: Invalidation

Request date: 20130603

Decision date: 20140610

Appeal identifier: 2013100001467

Appeal kind category: Invalidation

Request date: 20130516

Decision date: 20140610

Appeal identifier: 2013100001309

Appeal kind category: Invalidation

Request date: 20130325

Decision date: 20140610

Appeal identifier: 2013100000708

Appeal kind category: Invalidation

Request date: 20130322

Decision date: 20140610

Appeal identifier: 2013100000688

Patent event code: PJ13011S05D

Patent event date: 20140610

Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design)

Appeal kind category: Invalidation

Request date: 20130201

Decision date: 20140610

Appeal identifier: 2013100000257

J2X1 Appeal (before the patent court)

Free format text: TRIAL NUMBER: 2014200004913; INVALIDATION

PJ2001 Appeal

Patent event date: 20140610

Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design)

Patent event code: PJ20011S05I

Appeal kind category: Invalidation

Decision date: 20160121

Appeal identifier: 2014200004913

Request date: 20140710

FPAY Annual fee payment

Payment date: 20150119

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20150119

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20160119

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20160119

Start annual number: 8

End annual number: 8

J2X2 Appeal (before the supreme court)

Free format text: TRIAL NUMBER: 2016300000502; APPEAL BEFORE THE SUPREME COURT FOR INVALIDATION

PJ2002 Appeal before the supreme court

Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design)

Patent event date: 20140610

Patent event code: PJ20021S05I

Request date: 20160226

Appeal identifier: 2016300000502

Appeal kind category: Invalidation

Decision date: 20190131

J302 Written judgement (patent court)

Free format text: JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20140710

Effective date: 20160121

Free format text: TRIAL NUMBER: 2014200004913; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20140710

Effective date: 20160121

PJ1302 Judgment (patent court)

Patent event date: 20160422

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20140710

Decision date: 20160121

Appeal identifier: 2014200004913

Appeal kind category: Invalidation

FPAY Annual fee payment

Payment date: 20170201

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20170201

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20180201

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20180201

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20190129

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20190129

Start annual number: 11

End annual number: 11

J222 Remand (patent court)

Free format text: TRIAL NUMBER: 2019240001889; REMAND (PATENT COURT) FOR INVALIDATION

PJ2202 Remand (patent court)

Appeal identifier: 2019240001889

Decision date: 20190419

Request date: 20190212

Appeal kind category: Invalidation

J303 Written judgement (supreme court)

Free format text: TRIAL NUMBER: 2016300000502; JUDGMENT (SUPREME COURT) FOR INVALIDATION REQUESTED 20160226

Effective date: 20190131

PJ1303 Judgment (supreme court)

Comment text: Written Judgment (Supreme Court)

Patent event date: 20190215

Patent event code: PJ13031S01D

Decision date: 20190131

Appeal kind category: Invalidation

Request date: 20160226

Appeal identifier: 2016300000502

EXTG Ip right invalidated
PC2102 Extinguishment

Termination category: Others

Termination date: 20190524

J302 Written judgement (patent court)

Free format text: TRIAL NUMBER: 2019240001889; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20190212

Effective date: 20190419

PJ1302 Judgment (patent court)

Patent event date: 20190514

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20190212

Decision date: 20190419

Appeal identifier: 2019240001889

Appeal kind category: Invalidation